Genetic alterations of FGF receptors: an emerging field in clinical cancer diagnostics and therapeutics

References

• Turner N, Pearson A, Sharpe R et al.FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res.70(5), 2085–2094 (2010).
   PubMed Web of Science ®Google Scholar
• Katoh M. RNA technology targeted to the WNT signaling pathway. Cancer Biol. Ther.7(2), 265–267 (2008).
   PubMedGoogle Scholar
• Katoh M. WNT and FGF gene clusters. Int. J. Oncol.21(6), 1269–1273 (2002).
   PubMed Web of Science ®Google Scholar
• Eswarakumar VP, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev.16(2), 139–149 (2005).
   PubMed Web of Science ®Google Scholar
• Dailey L, Ambrosetti D, Mansukhani A, Basilico C. Mechanisms underlying differential responses to FGF signaling. Cytokine Growth Factor Rev.16(2), 233–247 (2005).
   PubMed Web of Science ®Google Scholar
• Zhang X, Ibrahimi OA, Olsen SK, Umemori H, Mohammadi M, Ornitz DM. Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J. Biol. Chem.281(23), 15694–15700 (2006).
   PubMed Web of Science ®Google Scholar
• Bae JH, Schlessinger J. Asymmetric tyrosine kinase arrangements in activation or autophosphorylation of receptor tyrosine kinases. Mol. Cells29(5), 443–448 (2010).
   PubMedGoogle Scholar
• Adnane J, Gaudray P, Dionne CA et al.BEK and FLG, two receptors to members of the FGF family, are amplified in subsets of human breast cancers. Oncogene6, 659–663 (1991).
   PubMed Web of Science ®Google Scholar
• Theillet C, Adelaide J, Louason G et al.FGFR1 and PLAT genes and DNA amplification at 8p12 in breast and ovarian cancers. Genes Chromosomes Cancer7(4), 219–226 (1993).
   PubMed Web of Science ®Google Scholar
• Xiao S, Nalabolu SR, Aster JC et al.FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome. Nat. Genet.18(1), 84–87 (1998).
   PubMed Web of Science ®Google Scholar
• Simon R, Richter J, Wagner U et al. High-throughput tissue microarray analysis of 3p25 (RAF1) and 8p12 (FGFR1) copy number alterations in urinary bladder cancer. Cancer Res.61(11), 4514–4519 (2001).
   PubMed Web of Science ®Google Scholar
• Rand V, Huang J, Stockwell T et al. Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas. Proc. Natl Acad. Sci. USA102(40), 14344–14349 (2005).
   PubMed Web of Science ®Google Scholar
• Freier K, Schwaenen C, Sticht C et al. Recurrent FGFR1 amplification and high FGFR1 protein expression in oral squamous cell carcinoma (OSCC). Oral Oncol.43(1), 60–66 (2007).
   PubMed Web of Science ®Google Scholar
• Lin WM, Baker AC, Beroukhim R et al. Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res.68(3), 664–673 (2008).
   PubMed Web of Science ®Google Scholar
• Missiaglia E, Selfe J, Hamdi M et al. Genomic imbalances in rhabdomyosarcoma cell lines affect expression of genes frequently altered in primary tumors: an approach to identify candidate genes involved in tumor development. Genes Chromosomes Cancer48(6), 455–467 (2009).
   PubMed Web of Science ®Google Scholar
• Stephens P, Edkins S, Davies H et al. A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nat. Genet.37(6), 590–592 (2005).
   PubMed Web of Science ®Google Scholar
• Easton DF, Pooley KA, Dunning AM et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature447(7148), 1087–1093 (2007).
   PubMed Web of Science ®Google Scholar
• Nakatani H, Sakamoto H, Yoshida T et al. Isolation of an amplified DNA sequence in stomach cancer. Jpn. J. Cancer Res.81(8), 707–710 (1990).
   PubMedGoogle Scholar
• Jang JH, Shin KH, Park JG. Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. Cancer Res.61(9), 3541–3543 (2001).
   PubMed Web of Science ®Google Scholar
• Davies H, Hunter C, Smith R et al. Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res.65(17), 7591–7595 (2005).
   PubMed Web of Science ®Google Scholar
• Pollock PM, Gartside MG, Dejeza LC et al. Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene26(50), 7158–7162 (2007).
   PubMed Web of Science ®Google Scholar
• Gartside MG, Chen H, Ibrahimi OA et al. Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma. Mol. Cancer Res.7(1), 41–54 (2009).
   PubMed Web of Science ®Google Scholar
• Camps J, Nguyen QT, Padilla-Nash HM et al. Integrative genomics reveals mechanisms of copy number alterations responsible for transcriptional deregulation in colorectal cancer. Genes Chromosomes Cancer48(11), 1002–1017 (2009).
   PubMedGoogle Scholar
• Chesi M, Nardini E, Brents LA et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of FGFR3. Nat. Genet.16(3), 260–264 (1997).
   PubMed Web of Science ®Google Scholar
• Cappellen D, De Oliveira C, Ricol D et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat. Genet.23(1), 18–20 (1999).
   PubMed Web of Science ®Google Scholar
• Nord H, Segersten U, Sandgren J et al. Focal amplifications are associated with high grade and recurrences in stage Ta bladder carcinoma. Int. J. Cancer126(6), 1390–1402 (2010).
   PubMed Web of Science ®Google Scholar
• Yagasaki F, Wakao D, Yokoyama Y et al. Fusion of ETV6 to fibroblast growth factor receptor 3 in peripheral T-cell lymphoma with a t(4;12)(p16;p13) chromosomal translocation. Cancer Res.61(23), 8371–8374 (2001).
   PubMedGoogle Scholar
• Zhang Y, Hiraishi Y, Wang H et al. Constitutive activating mutation of the FGFR3b in oral squamous cell carcinomas. Int. J. Cancer117(1), 166–168 (2005).
   PubMed Web of Science ®Google Scholar
• Goriely A, Hansen RM, Taylor IB et al. Activating mutations in FGFR3 and HRAS reveal a shared genetic origin for congenital disorders and testicular tumors. Nat. Genet.41(11), 1247–1252 (2009).
   PubMed Web of Science ®Google Scholar
• Bange J, Prechtl D, Cheburkin Y et al. Cancer progression and tumor cell motility are associated with the FGFR4 Arg 388 allele. Cancer Res.62(3), 840–847 (2002).
   PubMed Web of Science ®Google Scholar
• Spinola M, Leoni V, Pignatiello C et al. Functional FGFR4 Gly388Arg polymorphism predicts prognosis in lung adenocarcinoma patients. J. Clin. Oncol.23(29), 7307–7311 (2005).
   PubMed Web of Science ®Google Scholar
• Marks JL, McLellan MD, Zakowski MF et al. Mutational analysis of EGFR and related signaling pathway genes in lung adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4. PLoS One2(5), e426 (2007).
   Google Scholar
• Taylor JG 6th, Cheuk AT, Tsang PS et al. Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. J. Clin. Invest.119(11), 3395–3407 (2009).
   PubMed Web of Science ®Google Scholar
• Katoh M. Cancer genomics and genetics of FGFR2. Int. J. Oncol.33(2), 233–237 (2008).
   PubMed Web of Science ®Google Scholar
• Turner N, Lambros MB, Horlings HM et al. Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene29(14), 2013–2023 (2010).
   PubMed Web of Science ®Google Scholar
• Katoh M, Katoh M. FGFR2 and WDR11 are neighboring oncogene and tumor suppressor gene on human chromosome 10q26. Int. J. Oncol.22(5), 1155–1159 (2003).
   PubMedGoogle Scholar
• Meyer KB, Maia A-T, O’Reilly M et al. Allele-specific upregulation of FGFR2 increases susceptibility to breast cancer. PLoS Biol.6, e108 (2008).
   PubMed Web of Science ®Google Scholar
• Katoh Y, Katoh M. FGFR2-related pathogenesis and FGFR2-targeted therapeutics. Int. J. Mol. Med.23(3), 307–311 (2009).
   PubMed Web of Science ®Google Scholar
• Moffa AB, Tannheimer SL, Ethier SP. Transforming potential of alternatively spliced variants of FGFR2 in human mammary epithelial cells. Mol. Cancer Res.2(11), 643–652 (2004).
   PubMedGoogle Scholar
• Soler G, Nusbaum S, Varet B et al.LRRFIP1, a new FGFR1 partner gene associated with 8p11 myeloproliferative syndrome. Leukemia23(7), 1359–1361 (2009).
   PubMed Web of Science ®Google Scholar
• Katoh M. Dysregulation of stem cell signaling network due to germline mutation, SNP, Helicobacter pylori infection, epigenetic change, and genetic alteration in gastric cancer. Cancer Biol. Ther.6(6), 832–839 (2007).
   PubMed Web of Science ®Google Scholar
• Katoh M, Katoh M. WNT signaling pathway and stem cell signaling network. Clin. Cancer Res.13(14), 4042–4045 (2007).
   PubMed Web of Science ®Google Scholar
• Katoh Y, Katoh M. Hedgehog signaling, epithelial-to-mesenchymal transition, and miRNA. Int. J. Mol. Med.22(2), 271–275 (2008).
   PubMed Web of Science ®Google Scholar
• Katoh M, Katoh M. Integrative genomic analyses of CXCR4: transcriptional regulation of CXCR4 based on TGFb, Nodal, Activin signaling and POU5F1, FOXA2, FOXC2, FOXH1, SOX17, and GFI1 transcription factors. Int. J. Oncol.36(2), 415–420 (2010).
   PubMed Web of Science ®Google Scholar
• Mohammadi M, Froum S, Hamby JM et al. Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. EMBO J.17(20), 5896–5904 (1998).
   PubMed Web of Science ®Google Scholar
• Wedge SR, Kendrew J, Hennequin LF et al. AZD2171: a highly potent, orally bioavailable, VEGFR2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res.65(10), 4389–4400 (2005).
   PubMed Web of Science ®Google Scholar
• Trudel S, Li ZH, Wei E et al. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood105(7), 2941–2948 (2005).
   PubMed Web of Science ®Google Scholar
• Nakamura K, Yashiro M, Matsuoka T et al. A novel molecular targeting compound as FGFR2 phosphorylation inhibitor, Ki23057, for scirrhous gastric cancer. Gastroenterology131(5), 1530–1541 (2006).
   PubMed Web of Science ®Google Scholar
• Pan BS, Chan GK, Chenard M et al. MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res.70(4), 1524–1533 (2010).
   PubMed Web of Science ®Google Scholar
• Bhide RS, Lombardo LJ, Hunt JT et al. The antiangiogenic activity in xenograft models of brivanib, a dual inhibitor of vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinases. Mol. Cancer Ther.9(2), 369–378 (2010).
   PubMed Web of Science ®Google Scholar
• Wheeler DL, Dunn EF, Harari PM. Understanding resistance to EGFR inhibitors: impact on future treatment strategies. Nat. Rev. Clin. Oncol. DOI: 10.1038/nrclinonc.2010.97 (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Pao W, Wang TY, Riely GJ et al.KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med.2(1), e17 (2005).
   Google Scholar